Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study
ObjectiveExposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical antigens of tumors which can enhance the immune response. We aimed to explore the clinical efficacy and safety of Toripalimab combined with Anloti...
Main Authors: | Yongbiao Chen, Hanyin Hong, Wenzheng Fang, Xia Zhang, Huachun Luo, Zhijian Chen, Jianda Yu, Weiqiang Fan, Xiaobin Chi, Yonghai Peng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1113389/full |
Similar Items
-
Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: a retrospective controlled study
by: Song Chen, et al.
Published: (2023-11-01) -
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective studyResearch in context
by: Xu-Kun Wu, et al.
Published: (2024-01-01) -
Long-Term Outcomes of Stereotactic Body Radiotherapy (SBRT) for Intraprostatic Relapse after Definitive Radiotherapy for Prostate Cancer: Patterns of Failure and Association between Volume of Irradiation and Late Toxicity
by: Marcin Miszczyk, et al.
Published: (2023-02-01) -
Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
by: Ze-Rui Zhao, et al.
Published: (2021-01-01) -
Extreme Hypofractionation with SBRT in Localized Prostate Cancer
by: Maria Antonia Gómez-Aparicio, et al.
Published: (2021-08-01)